For example, a recent study reported that CCR2 blockade could enhance the efficacy of anti-PD-1 therapy in in vivo lung and mammary tumour models by reducing macrophage frequency in tumours; thereby reducing Treg expansion and increasing effector T cell infiltration [68, 69]. Here, CCR2 is linked to breast cancer.